Association between metabolic syndrome and psoriasis: a meta-analysis of observational studies with non-psoriasis control groups

Ju Qiao, Qian-Nan Jia, Hong-Zhong Jin

Department of Dermatology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

Submitted: 31 July 2018; Accepted: 9 January 2019
Online publication: 31 January 2020

Arch Med Sci 2021; 17 (6): 1558–1565
DOI: https://doi.org/10.5114/aoms.2020.92434
Copyright © 2020 Termedia & Banach

Abstract

Introduction: Psoriasis is a highly prevalent condition that affects the quality of life of affected individuals. Several studies have indicated an association between psoriasis and metabolic syndrome (MS). However, the results were inconsistent. The objective of this study was to evaluate the relationship between psoriasis and MS.

Material and methods: Electronic databases (PubMed, EBSCO, Elsevier, Springer, Wiley, and Cochrane) were searched systematically for published studies up to November 2, 2018. Odds ratio (OR) and 95% confidence interval (CI) were used to evaluate the association between psoriasis and MS. The heterogeneity of the study was estimated with the $I^2$ statistic and analyzed by meta-regression and subgroup analyses.

Results: Twenty-two studies with a total of 137,053 participants were included in this meta-analysis. Psoriasis was associated with MS, and the combined OR (95% CI) was 2.02 (1.67–2.43). The results showed high heterogeneity ($I^2 = 83.60\%$, $p < 0.001$) and no publication bias among the included studies ($p = 0.119$). The source of controls may have influenced the heterogeneity according to the meta-regression. There was no heterogeneity in studies with matched non-psoriasis control groups according to the subgroup analysis.

Conclusions: Psoriasis was associated with MS. The source of the control group was an influencing factor on heterogeneity in this study. Treating for MS in patients with psoriasis might improve psoriasis and reduce the risk of cardiovascular disease.

Key words: psoriasis, metabolic syndrome, observational studies, meta-analysis.

Introduction

Psoriasis is an inflammatory disease with visible manifestations that has no cure [1]. In 2016, psoriasis was estimated to affect 65 million people around the world [2]. Epidemiological studies have found that psoriasis is associated with metabolic syndrome (MS). Metabolic syndrome is typically defined based on at least three of the following medical conditions: obesity, dyslipidemia, hypertension, and hyperglycemia [3]. In Poland among 810 postmenopausal women, 34% were diagnosed with both the disorders [4]. In India, MS was significantly more...
common in psoriatic patients than in controls (42 (28%) vs. 9 (6%), and psoriatic patients also had a significantly higher prevalence of MS [5]. A study based on a large population in the UK by Langan et al. demonstrated that psoriasis and MS have a dose-response association. The incidence of MS is 22% in patients with mild psoriasis, 56% in moderate psoriasis, and 98% in severe psoriasis [6]. Additionally, a randomized controlled trial (RCT) suggested that treatment of MS, such as diet control, can improve the condition of psoriasis [7]. Another RCT study showed that psoriasis patients with MS can improve the condition of psoriasis with the treatment of insulin sensitizers [8].

It is believed that psoriasis pathogenesis is caused by a combination of innate and acquired immunity. When some pathogenic factors break through the skin, antibacterial peptides can destroy the body’s natural immune tolerance to its DNA/RNA and bind to form an immune complex. The complexes stimulate the dendritic cells, which in turn produce the cytokine interferon-α (IFN-α) mediated by TLR8, leading to the onset and persistence of psoriasis [9]. Psoriasis and MS are both chronic inflammatory diseases and the inflammatory response may be one common pathogenesis of them. Previous research has shown that serum C-reactive protein (CRP) levels are significantly higher in psoriasis patients with MS than psoriasis patients without MS [10]. The inflammatory component of psoriasis may affect MS components, and the mixture of inflammatory molecules and hormones of MS might impact psoriasis as well, such as tumor necrosis factor-α (TNF-α), interleukin (IL)-17 and IL-18 [11–13]. Boehncke et al. indicated that when psoriasis develops to a more severe degree, it forms systemic inflammation and causes insulin resistance, which in turn triggers endothelial cell dysfunction, leading to atherosclerosis and finally myocardial infarction or stroke [14].

Although previous studies have shown a significant association between psoriasis and MS, new studies have been published, and negative results were reported [15–17]. Our study included studies with non-psoriasis groups, which better assessed the association between psoriasis and MS. The objective of this study was to evaluate the relationship between psoriasis and MS.

Material and methods

Search strategy and selection criteria

This study was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. We searched electronic databases (PubMed, EBSCO, Elsevier, Springer, Wiley, and Cochrane) for studies published up to November 2, 2018 from the database inception and used the Mesh terms “psoriasis/metabolism” or “psoriasis/complications”. The inclusion criteria were as follows: (1) case-control or cross-sectional study, (2) association between MS and psoriasis reported by odds ratio (OR) and 95% confidence interval (CI), and (3) adult patients. The exclusion criteria were as follows: (1) duplication of research literature, (2) systematic reviews and meta-analyses, (3) studies not reported in English, (4) studies with no control group, and (5) OR of MS and psoriasis were not reported. We contacted the corresponding author in case we failed to obtain an article.

Data extraction

Ju Qiao and Qiannan Jia were in charge of data extraction. The data included the first author’s name, year of publication, type of study, number of patients (cases) and controls, age (mean), gender (male/female), diagnostic criteria for MS and psoriasis, adjusted OR reported or not, and ethical considerations.

Statistical analysis

We evaluated the association between MS and psoriasis using ORs and 95% CIs. The statistical heterogeneity of the study was estimated using the Q test and I² index. If there was no statistically significant heterogeneity (p > 0.1 and I² < 50%), a pooled effect was calculated with a fixed-effects model, whereas a random-effects model was employed otherwise (p < 0.1 or I² > 50%). We used Begg’s test and plot to assess the possible publication bias in the included studies. When heterogeneity was found, meta-regression was performed to assess whether publication year, study type (case-control or cross-sectional study), diagnostic criteria for MS (NCEP ATP III criteria or not), diagnosis of psoriasis (clinical diagnosis or not), adjusted OR reported or not, and source of controls were potential confounding factors. Subgroup analyses were conducted according to the result of the meta-regression. All statistical analyses were conducted using Stata version 11.0 (Stata Corp LLC, College Station, TX, USA). P-values less than 0.05 were considered statistically significant.

Results

Characteristics of included studies

We obtained 274 studies by systematic screening of the literature; 220 studies were excluded because they were found to be irrelevant after title and abstract reading. After further screening, 32 studies were excluded (one study was in Spanish, 10 studies had no control group, 17 studies did not report ORs, 3 studies were meta-analyses or systematic reviews and 1 was a case report.
| Author                  | Year | N     | Study type     | Diagnosis of MS                          | Diagnosis of psoriasis | Age  | M/F | Case | Control | Source of control | Adjusted OR | Ethics                           |
|------------------------|------|-------|----------------|-----------------------------------------|------------------------|------|-----|------|---------|-------------------|-------------|----------------------------------|
| Gui et al. [39]        | 2018 | 2577  | Cross-sectional| Criteria recommended by the Chinese Diabetes Society | Clinical diagnosis     | 41.29| 1641/936 | 859  | 1718  | Hospital non-PSA subjects | Age and gender | Ethics committee approved |
| Milić et al. [15]      | 2017 | 407   | Cross-sectional| NCEP-ATP III                          | Clinical diagnosis     | 49.60| 213/194 | 244  | 163   | Hospital non-psoriasis subjects | Age and gender | Written informed consent         |
| Koku Aksu et al. [16]  | 2017 | 477   | Cross-sectional| NCEP-ATP III                          | Clinical diagnosis     | 44.69| 237/240 | 300  | 177   | Hospital non-psoriasis subjects | No          | Ethics committee approved |
| Sharma et al. [18]     | 2016 | 200   | Case-control   | NCEP-ATP III                          | Clinical diagnosis     | 44.11| 130/70  | 100  | 100   | Hospital non-psoriasis subjects | No          | Written informed consent         |
| Kothiwa et al. [19]    | 2016 | 280   | Cross-sectional| NCEP-ATP III                          | Self report            | 37.00| 199/81  | 140  | 140   | Hospital non-psoriasis subjects | No          | Written informed consent         |
| Meziane et al. [20]    | 2016 | 450   | Case-control   | International Diabetes Foundation     | Clinical diagnosis     | 40.80| –       | 150  | 300   | Hospital non-psoriasis subjects | No          | Ethics committee approved |
| Itani et al. [21]      | 2016 | 300   | Case-control   | NCEP-ATP III                          | Clinical diagnosis     | 42.03| 135/165 | 150  | 150   | Hospital non-psoriasis subjects | Smoking     | Written informed consent & IRB approved |
| Raznatovic-Durovic et al. [22] | 2016 | 227   | Case-control   | NCEP-ATP III                          | Clinical diagnosis     | 46.50| 100/127 | 101  | 126   | Hospital non-psoriasis subjects | Age, gender, smoking, physical activity | Written informed consent |
| Miller et al. [23]     | 2015 | 14876 | Cross-sectional| NCEP-ATP III                          | Questionnaire          | –    | –       | 860  | 14016 | Hospital non-psoriasis subjects | Age, gender and smoking | Written informed consent         |
| Parodi et al. [24]     | 2014 | 734   | Cross-sectional| NCEP-ATP III                          | Clinical diagnosis     | 53.79| 403/331 | 390  | 344   | Hospital non-psoriasis subjects | Age, gender et al. | Written informed consent         |
| Damevska et al. [25]   | 2013 | 244   | Case-control   | NCEP-ATP III                          | Clinical diagnosis     | 51.75| 104/140 | 122  | 122   | Hospital non-psoriasis subjects | No          | Written informed consent         |
### Table I. Cont.

| Author              | Year | N    | Study type | Diagnosis of MS | Diagnosis of psoriasis | Age   | M/F        | Case | Control | Source of control | Adjusted OR | Ethics                                      |
|---------------------|------|------|------------|-----------------|------------------------|-------|------------|------|---------|-------------------|-------------|---------------------------------------------|
| Vaya et al. [17]    | 2012 | 192  | Case-control | NCEP-ATP III | Clinical diagnosis     | 51.27 | 98/94      | 91   | 101     | Population non-psoriasis subjects | Age gender et al. | Ethical guidelines approved                   |
| Arias-Santiago et al. [26] | 2012 | 133  | Case-control | NCEP-ATP III | Clinical diagnosis     | –     | 70/63      | 72   | 61      | Population non-psoriasis subjects | No | Written informed consent                   |
| Langan et al. [27]  | 2012 | 4471 | Cross-sectional | NCEP-ATP III | Questionnaire          | 45-65 | 21385/23330 | 4065 | 40650   | Population non-psoriasis subjects | Age, gender | IRB approved                                |
| Love et al. [28]    | 2011 | 2456 | Cross-sectional | NCEP-ATP III | Self-report             | 39.00 | 1183/1273 | 71   | 2385    | Population non-psoriasis subjects | Age, gender, race/ethnicity, smoking status and C-reactive protein levels | Written informed consent & IRB approved |
| Mebazaa et al. [29] | 2011 | 380  | Case-control | NCEP-ATP III | Clinical diagnosis     | 47.62 | 180/200    | 164  | 216     | Population non-psoriasis subjects | No | Written informed consent                   |
| Takahashi et al. [30] | 2010 | 305  | Case-control | Japan Committee for diagnostic criteria of metabolic syndrome | Clinical diagnosis | 55.17 | 218/87     | 151  | 154     | Population non-psoriasis subjects | No | No mention                                  |
| Chen et al. [31]    | 2009 | 77   | Case-control | NCEP-ATP III | Clinical diagnosis     | 57.48 | 54/23      | 40   | 37      | Population non-psoriasis subjects | No | IRB approved                                |
| Cohen et al. [32]   | 2008 | 65532| Case-control | Customize standard | Clinical diagnosis | 48.87 | 31812/33720 | 16,851 | 48,681 | Population non-psoriasis subjects | Age and gender | No mention                                   |
| Chen et al. [33]    | 2008 | 158  | Case-control | NCEP-ATP III | Clinical diagnosis     | 56.49 | 112/46     | 77   | 81      | Population non-psoriasis subjects | No | IRB approved                                |
| Gisondi et al. [34] | 2007 | 672  | Case-control | NCEP-ATP III | Clinical diagnosis     | 62.95 | 310/362    | 338  | 334     | Population non-psoriasis subjects | Age and gender | Written informed consent                |
| Sommer et al. [35]  | 2006 | 1625 | Case-control | WHO criteria | Clinical diagnosis     | 57.03 | 786/839    | 581  | 1,044   | Hospital non-psoriasis subjects | Age and gender | No mention                                  |
Finally, twenty-two studies [15–35] with a total of 137,053 participants were included in the meta-analysis (Figure 1, Table I).

Of the 22 included studies, 14 were case-control studies and the others were cross-sectional studies. In the diagnosis of MS, different criteria were used: the NCEPATP III was used in 18 studies, one study used the International Diabetes Foundation criteria [20], one used the Japanese Committee for the Diagnostic Criteria of Metabolic Syndrome, one used criteria recommended by the Chinese Diabetes Society, one used the WHO criteria and one was a customized standard [35].

In seventeen studies psoriasis was diagnosed clinically, two were based on self-report, and three used questionnaires. In the included studies, informed consent was obtained as well as approval by an institutional review board, but three studies did not describe ethical considerations.

**Quantitative synthesis**

In this meta-analysis, we found that psoriasis was associated with MS and the combined OR (95% CI) was 2.02 (1.67–2.43) with \( p < 0.001 \). The results are shown in Figure 2.
This analysis was subject to significant heterogeneity ($I^2 = 83.60\%, p < 0.001$). The data from the meta-regression are shown in Table II, and only the source of controls may have influenced the heterogeneity in our study.

Begg’s test was applied to assess the included literature’s publication bias in this study and no significant publication bias was found; the Egger’s test $p$-value was 0.119. The result is shown in Figure 3.

Discussion

We evaluated the relationship between psoriasis and MS using combined OR by meta-analysis. In our study, 22 case-control or cross-sectional studies were included, with 25,953 psoriasis patients and 111,100 controls. The age range of the participants was 37.00–65.00 years. Psoriasis was found to be associated with MS from the meta-analysis (OR = 2.02; 95% CI: 1.67–2.43) and is similar to the published meta-analysis study [36].

To the best of our knowledge, this is the first study to discuss the factor of heterogeneity in a meta-analysis of psoriasis and MS. We assessed potential factors including study type, MS diagnostic criteria, diagnosis of psoriasis, reported adjusted OR, and the source of non-psoriasis controls in the meta-regression. Of the five factors, only the source of controls significantly affected the heterogeneity ($p = 0.01$). In studies with matching non-psoriasis controls, the heterogeneity no longer existed according to the further subgroup analysis. The control group was established to better analyze the relationship between psoriasis and MS. In observational studies, the selection of control groups can significantly affect the results. Studies with matched control groups can be more accurate in describing the relationship between psoriasis and MS. Therefore, in our analysis, psoriasis was significantly associated with MS, especially in the studies with matched non-psoriasis control groups.

The underlying mechanism of the relationship between psoriasis and MS is complex. Psoriasis is an inflammatory disease involving many factors. One of them is high-sensitivity C-reactive protein (hs-CRP). Hs-CRP is a sensitive, nonspecific systemic inflammatory marker. Danielsen et al. found that psoriasis patients with elevated hs-CRP levels showed negative metabolic status, especially in women [37]. One study indicated that the mechanism of the association of psoriasis with atherosclerosis (one disease that may be caused by MS) was similar to the association of atherosclerosis with systemic lupus erythematosus [38]. Previous hospital-based cross-sectional studies have indicated that the duration of psoriasis may be a risk factor for MS [39, 40]. The chronic inflammatory level of psoriasis might give the explanation. Jensen et al. found that low-energy diet treatment led to a clinical improvement in the psoriasis area and severity index [41]. Therefore, the treatment of MS in patients with co-existing psoriasis could potentially lower the onset and severity of psoriasis.

IL-17 is a pro-inflammatory cytokine which is mainly secreted by activated Th-17 cells and the differentiation of Th-17 depends on IL-23 [42]. There is increasing evidence showing that the IL-23/Th17 signaling pathway is involved in the pathogenesis of psoriasis [43] and MS [11]. Higher levels of IL-17, IL-23 and TNF-$\alpha$ were observed in patients with MS accompanying psoriasis compared to pa-

\begin{table}[h!]
\centering
\caption{Table II. Results of meta-regression} 
\begin{tabular}{|l|c|c|c|c|c|
\hline
Variables & $b$ & $S_b$ & $t$ & $P$-value & 95\% CI \\
\hline
Type of study & -0.77 & 0.41 & -1.85 & 0.08 & -1.64 & 0.11 \\
Diagnosis of MS & 0.53 & 0.36 & 1.48 & 0.16 & -0.22 & 1.28 \\
Diagnosis of psoriasis & 0.97 & 0.49 & 1.96 & 0.07 & -0.08 & 2.01 \\
Adjusted OR & 0.16 & 0.30 & 0.54 & 0.60 & -0.48 & 0.80 \\
Source of control* & -1.02 & 0.35 & -2.94 & 0.01 & -1.75 & -0.29 \\
\hline
\end{tabular}
\*Source of control were divided into age and gender matched group and non-matched group. MS – metabolic syndrome, LCI – lower confidence interval, UCI – upper confidence interval.
\end{table}

\begin{figure}[h!]
\centering
\includegraphics[width=\textwidth]{fig3}
\caption{Begg’s funnel plot with pseudo 95\% confidence limits}
\end{figure}
patients with psoriasis without the features of this syndrome [44]. Rasmy et al. found that the IL-18 expression in the skin lesions was significantly lower than lesional skin after therapeutic interventions [45]. Recently, novel IL-17 and IL-23 antagonists for the treatment of psoriasis were approved by the Food and Drug Administration [46]. Many approaches in MS management may also treat psoriasis, such as omega-3 fatty acids and vitamins [47]. Clinical studies have confirmed that vitamin D can effectively reduce the levels of IL-17 and IL-17-expressing cells in psoriasis lesions [48]. In MS patients, taking vitamin D decreased systolic blood pressure by 3.7% [49].

Psoriasis, especially in combination with MS, has many complications. Akcali et al. reported that MS was more frequently identified in Turkish patients with psoriasis than in controls. Psoriasis patients with MS have a high risk of cardiovascular disease and believe that improvement of MS was beneficial to reducing the risk of cardiovascular disease [50].

This meta-analysis has several limitations. This study included 22 observational studies with non-psoriasis control groups, which provides better evidence to assess the relationship between psoriasis and MS. We also chose five factors to assess the origin of heterogeneity, and found that the source of controls in each study was a major determinant of heterogeneity. However, this meta-analysis may indicate, though not definitely, the association between psoriasis and MS. A relative cohort or experimental study needs to be conducted to explore the relationship between psoriasis and MS, and the underlying mechanism.

In conclusion, psoriasis was associated with MS according to our meta-analysis. The source of the control group had a significant effect on the combined OR value.

Conflict of interest

The authors declare no conflict of interest.

References

1. Uebe S, Ehrlicher M, Ekici AB, et al. Genome-wide association and targeted analysis of copy number variants with psoriatic arthritis in German patients. BMC Med Genet 2017; 18: 92.
2. GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 2017; 390: 1211-59.
3. Gorbachinsky I, Akpinar H, Assimios DG. Metabolic syndrome and urologic diseases. Rev Urol 2010; 12: e157-80.
4. Pinkas J, Bojar I, Owoc A, Wierzbinska-Stepniak A, Raczkiewicz D. Cardiovascular diseases, metabolic syndrome and health behaviours of postmenopausal women working in agriculture. Arch Med Sci 2017; 13: 1040-8.
5. Nisa N, Ozgi MA. Prevalence of metabolic syndrome in patients with psoriasis. Indian J Dermatol Venereol Leprol 2010; 76: 662-5.
6. Langan SM, Seminara NM, Shin DB, et al. Prevalence of metabolic syndrome in patients with psoriasis: a population-based study in the United Kingdom. J Invest Dermatol 2012; 132: 556-62.
7. Naldi L, Conti A, Cazzaniga S, et al.: Psoriasis Emilia Romagna Study Group. Diet and physical exercise in psoriasis: a randomized controlled trial. Br J Dermatol 2014; 170: 634-42.
8. Surjit S, Anil B. Randomized placebo control study of insulin sensitizers (Metformin and Pioglitazone) in psoriasis patients with metabolic syndrome (Topical Treatment Cohort). BMC Dermatol 2016; 16: 12.
9. Jiang W, Zhu FG, Bhatag L, et al. A Toll-like receptor 7, 8, and 9 antagonist inhibits Th1 and Th17 responses and inflammasome activation in a model of IL-23-induced psoriasis. J Invest Dermatol 2013; 133: 1777-84.
10. Shlyankevich I, Mehta NN, Krueger JG, et al. Accumulating evidence for the association and shared pathogenic mechanisms between psoriasis and cardiovascular-related comorbidities. Am J Med 2014; 127: 1148-53.
11. Mohamed R., Jayakumar C, Chen F, et al. Low-dose IL-17 therapy prevents and reverses diabetic nephropathy, metabolic syndrome, and associated organ fibrosis. J Am Soc Nephrol 2016; 27: 745-66.
12. Azfar RS, Gelfand JM. Psoriasis and metabolic disease: epidemiology and pathophysiology. Curr Opin Rheumatol 2008; 20: 416-22.
13. Michalski B, Szymczyk E, Peczek L, et al. The role of selected adipokines and ghrelin in the prognosis after myocardial infarction in a 12-month follow-up in the presence of metabolic syndrome. Arch Med Sci 2017; 13: 785-94.
14. Boehncke WH, Boehncke S, Tobin AM, Kirby B. The ‘psoriatic march’: a concept of how severe psoriasis may drive cardiovascular comorbidity. Exp Dermatol 2011; 20: 303-7.
15. Miličić D, Janković S, Vesić S, et al. Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based cross-sectional study. An Bras Dermatol 2017; 92: 46-51.
16. Koku Akşu AE, Saracoğlu ZN, Metintas S, et al. Age and gender differences in Framingham risk score and metabolic syndrome in psoriasis patients: a cross-sectional study in the Turkish population. Anatol J Cardiol 2017; 17: 66-72.
17. Vaya A, Ricart JM, Andino B, et al. Psoriasis and hemorrhology. Influence of the metabolic syndrome. Clin Hemorheol Microcirc 2013; 55: 331-9.
18. Sharma YK, Prakash N, Gupta A. Prevalence of metabolic syndrome as per the NCEP and IDF definitions vis-à-vis severity and duration of psoriasis in a semi-urban Maharashtrian population: a case control study. Diabetes Metab Syndr 2016; 10 (2 Suppl 1): S72-6.
19. Kothiwala SK, Khatna N, Tandon N, et al. Prevalence of metabolic syndrome and cardiovascular changes in patients with chronic plaque psoriasis and their correlation with disease severity: a hospital-based cross-sectional study. Indian J Dermatol Venereol Leprol 2016; 82: 510-8.
20. Meżiane M, Kelati A, Najdi A, Berraho A, Nejjari C, Mernissi FZ. Metabolic syndrome in Moroccan patients with psoriasis. Int J Dermatol 2016; 55: 396-400.
21. Itani S, Arabi A, Harb D, Hamzeh D, Kibbi AG. High prevalence of metabolic syndrome in patients with psoriasis in Lebanon: a prospective study. Int J Dermatol 2016; 55: 390-5.
Association between metabolic syndrome and psoriasis: a meta-analysis of observational studies with non-psoriasis control groups

22. Raznatovic-Durovic M, Jankovic J, Jankovic S. Prevalence of metabolic syndrome in Montenegrin patients with psoriasis. Vojnosanit Pregl 2016; 73: 1065-72.

23. Miller IM, Ellervik C, Zarchi K, et al. The association of metabolic syndrome and psoriasis: a population-and hospital-based cross-sectional study. J Eur Acad Dermatol Venereol 2015; 29: 490-7.

24. Parodi A, Aste N, Calviere C, et al. Metabolic syndrome prevalence in psoriasis: a cross-sectional study in the Italian population. J Clin Dermatol 2014; 15: 371-7.

25. Damevska K, Neloska L, Goece G, Mihova M. Metabolic syndrome in untreated patients with psoriasis: case-control study. J Dtsch Dermatol Ges 2013; 11: 1169-75.

26. Arias-Santiago S, Orgaz-Molina J, Castellote-Caballero L, et al. Atheroma plaque, metabolic syndrome and inflammation in patients with psoriasis. Eur J Dermatol 2012; 22: 337-44.

27. Langan SM, Seminara NM, Shin DB, et al. Prevalence of metabolic syndrome in patients with psoriasis: a population-based study in the United Kingdom. J Invest Dermatol 2012; 132: 556-62.

28. Love TJ, Quareshi AA, Karlson EW, Gelfand JM, Choi HK. Prevalence of the metabolic syndrome in psoriasis: results from the National Health and Nutrition Examination Survey 2003-2006. Arch Dermatol 2011; 147: 419-24.

29. Danielsen K, Wilsgaard T, Olsen AO, et al. Elevated odds of metabolic syndrome in patients with moderate to severe psoriasis. J Invest Dermatol 2009; 129: 705-9.

30. Takahashi H, Takahashi I, Homma M, Ishida-Yamamoto A, Iizuka H. Prevalence of metabolic syndrome in Japanese psoriasis patients. J Dermatol Sci 2010; 57: 143-4.

31. Chen YJ, Shen JL, Wu CY, Chang YT, Chen CM, Lee FY. Elevated plasma osteopontin level is associated with occurrence of psoriasis and is an unfavorable cardiovascular risk factor in patients with psoriasis. J Am Acad Dermatol 2009; 60: 225-30.

32. Cohen AD, Shef F, Vidavsky L, Vardy DA, Shapiro J, Meeyrovnitch J. Association between psoriasis and the metabolic syndrome. A cross-sectional study. Dermatology 2008; 216: 152-5.

33. Chen YJ, Wu CY, Shen JL, et al. Psoriasis independently associated with hyperleptinemia contributing to metabolic syndrome. Arch Dermatol 2008; 144: 1571-5.

34. Gisondi P, Tessari G, Conti A, et al. Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case-control study. Br J Dermatol 2007; 157: 68-73.

35. Sommer DM, Jenisch S, Suchan M, Christophers E, Weichenthal M. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch Dermatol Res 2006; 298: 321-8.

36. Armstrong AW, Harskamp CT, Armstrong EJ. Psoriasis and metabolic syndrome: a systematic review and meta-analysis of observational studies. J Am Acad Dermatol 2013; 68: 654-62.

37. Danielsen K, Wilsgaard T, Olsen AO, et al. Elevated odds of metabolic syndrome in psoriasis: a population-based study of age and sex differences. Br J Dermatol 2015; 172: 419-27.

38. Cohen AD, Gilutz H, Henkin Y, et al. Psoriasis and the metabolic syndrome. Acta Derm Venereol 2007; 87: 506-9.

39. Gui XY, Xu XL, Jin HZ, Zuo YG, Wu C. Prevalence of metabolic syndrome in Chinese psoriasis patients: a hospital-based cross-sectional study. J Diabetes Investig 2018; 9: 39-43.

40. Nisa N, Qazi MA. Prevalence of metabolic syndrome in patients with psoriasis. Indian J Dermatol Venereol Leprol 2010; 76: 662-5.